CA3180411A1 - Methods of using rho kinase inhibitors to treat vascular dementia - Google Patents

Methods of using rho kinase inhibitors to treat vascular dementia Download PDF

Info

Publication number
CA3180411A1
CA3180411A1 CA3180411A CA3180411A CA3180411A1 CA 3180411 A1 CA3180411 A1 CA 3180411A1 CA 3180411 A CA3180411 A CA 3180411A CA 3180411 A CA3180411 A CA 3180411A CA 3180411 A1 CA3180411 A1 CA 3180411A1
Authority
CA
Canada
Prior art keywords
patient
fasudil
dementia
patients
rho kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180411A
Other languages
English (en)
French (fr)
Inventor
Thomas Macallister
Sven Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3180411A1 publication Critical patent/CA3180411A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3180411A 2020-06-15 2021-01-08 Methods of using rho kinase inhibitors to treat vascular dementia Pending CA3180411A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063039141P 2020-06-15 2020-06-15
US63/039,141 2020-06-15
US202063046173P 2020-06-30 2020-06-30
US63/046,173 2020-06-30
PCT/US2021/012590 WO2021257122A1 (en) 2020-06-15 2021-01-08 Methods of using rho kinase inhibitors to treat vascular dementia

Publications (1)

Publication Number Publication Date
CA3180411A1 true CA3180411A1 (en) 2021-12-23

Family

ID=79268240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180411A Pending CA3180411A1 (en) 2020-06-15 2021-01-08 Methods of using rho kinase inhibitors to treat vascular dementia

Country Status (7)

Country Link
US (1) US20230285409A1 (enExample)
EP (1) EP4164652A4 (enExample)
JP (1) JP2023530120A (enExample)
CN (1) CN116249532A (enExample)
CA (1) CA3180411A1 (enExample)
MX (1) MX2022015800A (enExample)
WO (1) WO2021257122A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023097151A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
WO2024243197A2 (en) * 2023-05-24 2024-11-28 Woolsey Pharmaceuticals, Inc. Method of treating patients with notch3 mutations
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease
WO2025101834A1 (en) * 2023-11-10 2025-05-15 Woolsey Pharmaceuticals, Inc. Methods of treating sporadic cerebral small vessel disease
CN119954776A (zh) * 2025-03-03 2025-05-09 中国药科大学 一种法舒地尔二氯乙酸盐的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
EP2061314A4 (en) * 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
US20110237600A1 (en) * 2008-05-12 2011-09-29 Amnestix, Inc. Compounds for improving learning and memory
US20140199318A1 (en) * 2011-08-12 2014-07-17 Max-Del-Bruck-Centrum Fur Molekulare Medizin Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
EP2961405A4 (en) * 2012-12-14 2017-03-29 The Brigham and Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
MX2022009479A (es) * 2020-02-10 2022-08-22 Woolsey Pharmaceuticals Inc Metodos para tratar afeccion pseudobulbar y otras alteraciones emocionales.

Also Published As

Publication number Publication date
US20230285409A1 (en) 2023-09-14
EP4164652A4 (en) 2024-07-10
WO2021257122A1 (en) 2021-12-23
MX2022015800A (es) 2023-01-24
EP4164652A1 (en) 2023-04-19
JP2023530120A (ja) 2023-07-13
CN116249532A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
EP4164652A1 (en) Methods of using rho kinase inhibitors to treat vascular dementia
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US11666583B2 (en) Methods of treating cortical dementia associated wandering
US20230263806A1 (en) Methods of treating proteinopathies
EP4232041A1 (en) Methods of treating 4-repeat tauopathies
US20230405017A1 (en) Methods of using rho kinase inhibitors to treat frontotemporal dementia
EP4203960A1 (en) Methods of treating age-related cognitive decline
WO2021162808A1 (en) Methods of treating pseudobulbar affect and other emotional disturbances
EP4203961A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241223

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION REQUEST RECEIVED

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250219

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250317

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250317

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION DETERMINED COMPLIANT

Effective date: 20250317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250320

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250320

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219